This compound is a derivative of camptothecin, exhibiting potent inhibition of topoisomerase I, which halts the division of rapidly proliferating cancer cells, particularly in solid tumors. It is under development as a chemotherapeutic agent for various cancers, including colorectal, lung, and ovarian cancers.

Compared to the parent camptothecin, its structure offers improved stability and bioavailability, enhancing efficacy while reducing certain side effects, such as gastrointestinal irritation. Additionally, it effectively crosses the blood-brain barrier, showing potential for treating central nervous system tumors.

Currently, it is in clinical trials to evaluate safety and efficacy in patients, especially those resistant to other chemotherapies. It is also used in research as a biochemical tool to study DNA-enzyme interactions, cellular responses to DNA damage, and topoisomerase I inhibition mechanisms. While promising, it is not yet clinically approved and remains primarily in laboratory, preclinical, and clinical research settings.